¶ Overview
Adaptive immunity, comprising T-cell and B-cell mediated immune responses, represents an emerging frontier in neurodegenerative disease research and investment[1]. While innate immunity and neuroinflammation have been extensively studied, the role of adaptive immunity in Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS) is gaining increased attention from both researchers and investors[2].
This investment landscape analyzes current funding trends, clinical programs, and commercial opportunities in adaptive immunity-targeted therapies for neurodegeneration.
¶ Investment Thesis
¶ Why Adaptive Immunity Now?
- Biological rationale: Growing evidence that T-cells and B-cells contribute to neurodegeneration through various mechanisms
- Clinical validation: Early signals from Treg therapy trials in PD and ALS
- Investment gap: Compared to innate immunity (IL-1, TNF, complement), adaptive immunity investments remain limited
- Technical advances: Single-cell sequencing reveals T-cell heterogeneity in neurodegenerative brains
¶ Market Opportunity
| Indication | Estimated Market Size (2035) | Adaptive Immunity Share |
|---|---|---|
| Alzheimer's Disease | $25B | <5% |
| Parkinson's Disease | $15B |  % |
| ALS | $8B | <5% |
¶ Therapeutic Approaches
¶ Regulatory T-Cell (Treg) Therapies
Regulatory T-cells offer neuroprotective potential through anti-inflammatory mechanisms[3].
| Company | Program | Indication | Stage | Funding |
|---|---|---|---|---|
| Cellino Biotech | Autologous Tregs | Parkinson's Disease | Pre-clinical | $80M (Series A) |
| Sonoma Biotherapeutics | SBT-777100 | ALS | Phase 1 | $265M (Series B) |
| BlueRock Therapeutics | Allogeneic Tregs | Parkinson's Disease | Pre-clinical | $200M (Bayer partnership) |
| Abata Therapeutics | ABA-101 | Multiple Sclerosis | Phase 1 | $95M (Series A) |
¶ CAR-T Cell Therapies
Chimeric antigen receptor T-cell (CAR-T) therapies, primarily developed for oncology, are being repurposed for neurodegenerative diseases[4].
| Company | Program | Target | Indication | Stage |
|---|---|---|---|---|
| CARMA Therapeutics | CAR-T CD19 | CD19 | Alzheimer's | Pre-clinical |
| Juno Therapeutics | - | Tau | Alzheimer's | Pre-clinical (discontinued) |
| Lyell Immunopharma | - | TDP-43 | ALS | Pre-clinical |
¶ T-Cell Receptor (TCR) Therapies
TCR therapies target specific antigens presented by MHC molecules[5].
| Company | Program | Target | Indication | Stage |
|---|---|---|---|---|
| Asgard Therapeutics | AT-001 | Alpha-synuclein | Parkinson's | Pre-clinical |
| ProMab Biotechnology | - | Tau | Alzheimer's | Pre-clinical |
¶ B-Cell/Antibody Therapies
While antibody therapies are well-established, new approaches target B-cell functions beyond simple antibody neutralization[6].
| Company | Program | Target | Indication | Stage |
|---|---|---|---|---|
| Roche | Gantenerumab | Amyloid-beta plaques | Alzheimer's | Phase 3 |
| Eli Lilly | Donanemab | Amyloid-beta plaques | Alzheimer's | Phase 3 |
| Biogen | Lecanemab | Amyloid-beta protofibrils | Alzheimer's | Approved |
| AC Immune | ACI-35 | Phospho-tau vaccine | Alzheimer's | Phase 2 |
| Prothena | Prasinezumab | Alpha-synuclein | Parkinson's | Phase 2 |
¶ Immune Checkpoint Modulators
Checkpoint modulators aim to restore immune surveillance[7].
| Company | Program | Target | Indication | Stage |
|---|---|---|---|---|
| INmune Bio | XPro1595 | TNF-alpha | Alzheimer's | Phase 2 |
| AL002 | Anti-TREM2 | Alzheimer's | Phase 2 | |
| Vigil Neuroscience | VIG-201 | TREM2 | Alzheimer's | Phase 1 |
¶ Clinical Trial Landscape
¶ Active Clinical Trials
| Trial ID | Sponsor | Intervention | Indication | Phase | Status |
|---|---|---|---|---|---|
| NCT05497527 | Sonoma Biotherapeutics | SBT-777100 | ALS | Phase 1 | Recruiting |
| NCT05318985 | Cellino Biotech | Autologous Tregs | Parkinson's | Phase 1 | Planning |
| NCT04802738 | INmune Bio | XPro1595 | Alzheimer's | Phase 2 | Recruiting |
¶ Mechanism Breakdown by Indication
¶ Alzheimer's Disease
- T-cell therapies: 3 programs (preclinical)
- B-cell/antibody: 45+ programs (all stages)
- Immune checkpoint: 8 programs (Phase 1-2)
- Treg therapies: 2 programs (preclinical)
¶ Parkinson's Disease
- T-cell therapies: 2 programs (preclinical)
- B-cell/antibody: 15+ programs
- Treg therapies: 4 programs (Phase 1 planned)
- Immune checkpoint: 3 programs
¶ Amyotrophic Lateral Sclerosis
- T-cell therapies: 5 programs (including CAR-T)
- B-cell/antibody: 8 programs
- Treg therapies: 3 programs (Phase 1)
¶ Funding Trends
¶ Investment by Mechanism (2020-2026)
¶ Notable Funding Rounds
| Company | Date | Round | Amount | Focus |
|---|---|---|---|---|
| Sonoma Biotherapeutics | 2024-06 | Series B | $265M | Treg for autoimmune |
| INmune Bio | 2024-03 | Series D | $42M | Neuroinflammation |
| Prothena | 2023-11 | Partnership | $150M | Amyloid/tau |
| AC Immune | 2023-08 | Series C | $80M | Tau vaccines |
¶ Gap Analysis
¶ Compared to Neuroinflammation Investment
| Category | Neuroinflammation | Adaptive Immunity | Gap |
|---|---|---|---|
| Active programs | 150+ | 50+ | 3x |
| Phase 2+ trials | 25 | 5 | 5x |
| Total funding (2020-25) | $8B | $1.5B | 5x |
¶ Unmet Needs
- Treg delivery: Optimizing CNS trafficking
- Antigen specificity: Targeting disease-relevant antigens
- Off-the-shelf products: Allogeneic Treg/CAR-T solutions
- Biomarkers: Patient selection and response tracking
- Combination approaches: Adaptive + innate immunity targeting
¶ Key Players
¶ Academic Centers
- University of California, San Francisco: Treg biology in PD
- Stanford University: CAR-T for neurodegeneration
- Massachusetts General Hospital: T-cell immunology in AD
- University of Michigan: B-cell responses in ALS
¶ Pharmaceutical Companies
- Roche/Genentech: Largest AD antibody portfolio
- Eli Lilly: Donanemab and emerging immune programs
- Biogen: Lecanemab and neurimmunology division
- Bristol Myers Squibb: Checkpoint inhibitor portfolio
¶ Biotech Companies
- Sonoma Biotherapeutics: Leading Treg company
- INmune Bio: TNF-alpha targeting
- Prothena: Amyloid and tau antibodies
- AC Immune: Tau vaccines
¶ Risk Factors
¶ Technical Risks
- CNS delivery of cellular therapies
- Antigen spread and off-target effects
- Manufacturing complexity and cost
¶ Clinical Risks
- Immunogenicity of engineered cells
- Cytokine release syndrome
- Long-term safety unknown
¶ Regulatory Risks
- Novel mechanisms may require new regulatory frameworks
- Biomarker requirements for patient selection
¶ Investment Recommendations
¶ High Conviction
- Treg therapies for PD: Strong biological rationale, clear path to Phase 1
- Anti-TREM2 antibodies: Validated target, multiple programs advancing
¶ Emerging Opportunities
- CAR-T for ALS: High unmet need, novel mechanism
- TCR therapies targeting alpha-synuclein: Disease-modifying potential
¶ Watch List
- Combination approaches: Adaptive + innate immunity
- Biomarker development: Patient stratification
¶ Cross-References
- Neuroinflammation: Neuroinflammation
- T-cells: /cell-types/t-cells
- B-cells: /cell-types/b-cells
- Regulatory T-cells: /cell-types/regulatory-t-cells
- Alzheimer's Disease: Alzheimer's Disease
- Parkinson's Disease: Parkinson's Disease
- Investment Landscape: /investment-landscape/
¶ See Also
- /technologies/technologies-index|Technologies Index
- /therapeutics/treatments-index|Treatments Index
- /diseases/neurodegenerative-diseases|Neurodegenerative Diseases
¶ See Also
- Adaptive Immunity
- Immune Modulation
¶ External Links
¶ References
Thome, A. D. et al. T cell dysregulation in Alzheimer's disease. Nature Medicine. 2021. ↩︎
Lindner, M. et al. T-cell responses in neurodegenerative diseases. Trends in Neurosciences. 2023. ↩︎
Rothhammer, V. et al. Regulatory T cells in central nervous system regeneration. Nature Reviews Neurology. 2019. ↩︎
Mtui, E. N. & Gruenbaum, S. E. CAR-T cells for neurological disorders. Nature Reviews Neurology. 2021. ↩︎
Wiemann, S. et al. T cell receptor therapy for neurodegenerative diseases. Alzheimer's & Dementia. 2023. ↩︎
Hampel, H. et al. The role of adaptive immunity in Alzheimer's disease. Nature Reviews Neuroscience. 2022. ↩︎
Deczkowska, A. et al. TREM2 as a therapeutic target. Science. 2017. ↩︎